Open AccessImpact of SARS-CoV-2 on neuropsychiatric disorders
Author(s) -
María de los Ángeles Robinson-Agramonte,
CarlosAlberto Gonçalves,
Eleoris-García,
Naybí Préndes Rivero,
Anna Lisa Brigida,
Stanley G. Schultz,
Dario Siniscalco,
Ramiro Jorge García García
Publication year - 2021
Publication title -
world journal of psychiatry
Language(s) - English
Resource type - Journals
ISSN - 2220-3206
DOI - 10.5498/wjp.v11.i7.347
Subject(s) - medicine , covid-19 , psychiatry , bioinformatics , biology , disease , infectious disease (medical specialty)
Evolving data show a variable expression of clinical neurological manifestations in patients suffering with coronavirus disease 2019 (COVID-19) from early disease onset. The most frequent symptoms and signs are fatigue, dizziness, impaired consciousness, ageusia, anosmia, radicular pain, and headache, as well as others. Based on the high number of series of cases reported, there is evidence for the implication of the immune system in the pathological mechanism of COVID-19. Although the exact role of the immunological mechanism is not elucidated, two main mechanisms are suggested which implicate the direct effect of severe acute respiratory syndrome coronavirus 2 infection in the central nervous system and neuroinflammation. In the context of neurological manifestations associated with COVID-19, neuropsychiatric disorders show an exacerbation and are described by symptoms and signs such as depression, anxiety, mood alterations, psychosis, post-traumatic stress disorder, delirium, and cognitive impairment, which appear to be common in COVID-19 survivors. A worsened score on psychopathological measures is seen in those with a history of psychiatric comorbidities. We review the neuropsychiatric manifestations associated with COVID-19 and some critical aspects of the innate and adaptive immune system involved in mental health disorders occurring in COVID-19.